Certainly with respect to cancers of the lung, prostate and colon, which rely in part upon EGFR signaling for tumor growth and survival, dual targeting of IGF-1R and EGFR has garnered much interest, given the fact that reciprocal inhibition of one RTK in epithelial cancers often enhances expression of the other. This evidence concerns the gene IGF1R and cancer.